Scios Natrecor Pharmacoeconomic Study To Address Length Of Stay Concerns
Executive Summary
Scios Natrecor pharmacoeconomic study will address advisory committee concern about a one-day longer hospital stay for Natrecor than for nitroglycerin, CEO Richard Brewer told analysts following the committee meeting May 25.
You may also be interested in...
Scios To Launch Heart Failure Registry Simultaneous With Natrecor Marketing
Scios will initiate a congestive heart failure patient registry in conjunction with the launch of Natrecor (nesiritide) for treatment of acute decompensated CHF, CEO Richard Brewer said July 10.
Scios To Launch Heart Failure Registry Simultaneous With Natrecor Marketing
Scios will initiate a congestive heart failure patient registry in conjunction with the launch of Natrecor (nesiritide) for treatment of acute decompensated CHF, CEO Richard Brewer said July 10.
CHF Drug Trial Standards Debated By Natrecor Advisory Committee
If sponsors of acute congestive heart failure drug studies need to limit the patient population, they should focus on non-catheterized patients, FDA Cardio-Renal Drug Products Division Director Raymond Lipicky, MD, suggested during a May 25 advisory committee meeting.